Awarded for Five Consecutive Years! CMS’s Subsidiary Shenzhen Kangzhe Once Again Listed in “Shenzhen Top 500 Enterprises”

2025-10-28

On October 28, the “2025 Shenzhen Top 500 Enterprises” list, released by the Shenzhen Enterprise Confederation and Shenzhen Entrepreneur Association, was officially announced. Shenzhen Kangzhe Pharmaceutical Co., Ltd. (“Shenzhen Kangzhe”), a wholly-owned subsidiary of China Medical System Holdings Limited (“CMS” or “the Group”), was once again made the list with honor, ranking at 166th, by virtue of its steady operational performance, outstanding innovation capabilities, and sustained social contributions. Additionally, Shenzhen Kangzhe was also included in the “2025 Top 100 Most Efficient Enterprises of the Shenzhen Top 500” and the “2025 Top 100 Enterprises with the Highest Social Contributions of the Shenzhen Top 500”.     The five consecutive listings of Shenzhen Kangzhe not only reflect the high recognition of its remarkable operational resilience and vibrant innovation vitality in the complex market environment, but also demonstrate the Group’s continuous improvement in scale efficiency and the accelerated release of its quality growth […]

CMS Signed A Distribution Agreement for Ophthalmic Drugs Lucentis® and Beovu®

2025-10-27

Ranibizumab Injection (“Lucentis®”) is the first anti-VEGF drug approved for ophthalmic use in China. It is also currently the anti-VEGF drug in China that covers the widest age range and has the most indications[1], with its efficacy and safety verified by more than 200 clinical studies Brolucizumab Injection (“Beovu®”) is the current anti-VEGF drug with the smallest molecular weight (only 26 kDa). The producthas been approved for DME and recommended as a first-line therapy by the authoritative guideline[2]. In the global Phase 3 KESTREL and KITE Studies, Beovu® met all primary efficacy endpoints and the visual benefit persisted until Week 100, while showing superiority in fluid resolution. The median number of injections of Beovu® in the first year (7 times) was lower than that of aflibercept (9 times), while its overall safety profile was comparable to the latter Both collaborative products have been approved for marketing in China, and they will generate strong synergies with CMS Vision’s […]